Form 4: BioLife Solutions Exec Sells Shares Under 10b5-1 Plan

BioLife Solutions' Chief Quality and Operations, Karen A. Foster, sold 2,577 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Karen A. Foster, Chief Quality and Operations of BioLife Solutions Inc. (BLFS), reported a sale of common stock.
• On March 23, 2026, Foster sold 2,577 shares of BLFS common stock.
• The shares were sold at a weighted average price of $19.17 per share, with individual transactions ranging from $18.99 to $19.35.
• This transaction was executed pursuant to a Rule 10b5-1(c) trading plan, which became effective on December 4, 2025.
• Following this sale, Foster beneficially owns 108,758 shares of BioLife Solutions common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it is an insider sale, the execution under a pre-established 10b5-1 plan mitigates concerns about its implications for the company's immediate prospects.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned sale rather than a reaction to new, non-public information.

Negatives

• An insider sale, even if planned, reduces the insider's direct ownership stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider sales under 10b5-1 plans are common across various industries, particularly for executives managing personal liquidity or diversification, and typically do not reflect specific industry trends unless the volume is unusually high or widespread across multiple insiders.

Stakeholder Impact

• Minor impact on shareholders as a small number of shares were sold by an executive, which is a routine occurrence under a 10b5-1 plan and unlikely to significantly affect market perception or company operations.

Key Dates

Recommendation

The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 plan. This type of transaction is generally not indicative of new material information about the company's performance or future prospects, thus a 'hold' recommendation is appropriate as this filing alone does not provide a basis for a change in investment thesis.

Keywords

BioLife Solutions, BLFS, Insider Trading, Form 4, Stock Sale, Karen A. Foster, 10b5-1 Plan, Equity Transaction